

## CURRICULUM VITAE

Tracy Lynne Skaer, B.Pharm., Pharm.D., FASHP, FASCP

### CONTACT INFORMATION

**Business Address:** Department of Pharmacotherapy, College of Pharmacy  
Washington State University Health Sciences  
Health Sciences Building Suite 210  
PO Box 1495  
Spokane, WA 99210-1495

**Business Telephone:** (509) 358-7724

**Business FAX:** (509) 358-7744

**E-Mail:** tskaer@wsu.edu

### EDUCATION

2007 UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL – Graduate Certificate  
Center for Mindfulness in Medicine, Health Care, and Society – Sabbatical Leave  
Summer Intensive Practicum in Mindfulness-Based Stress Reduction

2001 UNIVERSITY OF SOUTH CAROLINA – Graduate Certificate  
Financial Management, Moore Graduate School of Business

2000 UNIVERSITY OF CALIFORNIA AT LOS ANGELES - Graduate Certificate  
Women's Leadership Institute, Anderson Graduate School of Business

1998 CORNELL UNIVERSITY - Graduate Certificate  
Administrative Management Institute for Higher Education, Johnson Graduate School of Business

1989-1990 UNIVERSITY OF SOUTHERN CALIFORNIA Doctor of Pharmacy (*Summa Cum Laude*)

1981-1985 WASHINGTON STATE UNIVERSITY - Bachelor of Pharmacy

1979-1981 SPOKANE FALLS COMMUNITY COLLEGE - Associate of Arts

### PROFESSIONAL EXPERIENCE

2002-present Professor of Pharmacotherapy (Tenured), College of Pharmacy, Washington State University

2002-2007 Professor of Health Policy & Administration (Tenured) Washington State University

1998-2008 Associate Director, Pharmacoeconomics & Pharmacoepidemiology Research Unit (PPRU),  
College of Pharmacy, Washington State University

1998-2003 Assistant Dean for Curriculum Design and Evaluation, College of Pharmacy, Washington State  
University

1997-2002 Associate Professor of Pharmacotherapy (Tenured), College of Pharmacy, Washington State  
University

1991-2007 Clinical Pharmacist, Pullman Regional Hospital, Pullman, Washington

1992-1998 Director, Residency Program in Rural Ambulatory Care, College of Pharmacy, Washington State  
University. [Clinical sites: Pullman Regional Hospital, Whitman County Home Health and Hospice;  
Funded via PPRU grants at Washington State University]

1991-1996 Assistant Professor of Pharmacotherapy, College of Pharmacy, Washington State University

1987-1988 Director, Pharmacy Home Care Service, Palmetto Richland Memorial Hospital, Columbia, South  
Carolina

1986-1987 Hospital Pharmacist, Palmetto Richland Memorial Hospital, Columbia, South Carolina

1985-1986 Accredited Residency, American Society of Health-System Pharmacists, Palmetto Richland  
Memorial Hospital, Columbia, South Carolina

### INTERDISCIPLINARY COLLABORATIONS

2016-present Member, Chronic Pain / Opioids / Cannabinoids Research Cluster, Translational Addiction  
Research Center, Washington State University

2011-present Member, Human Animal Interaction Interest Group, College of Veterinary Medicine, Washington  
State University.

1998-2012 Member, Pharmacoeconomics & Pharmacoepidemiology Research Unit, College of Pharmacy,  
Washington State University

2002-2009 Member, Gendering Research Across the Campuses, Washington State University

- 2005-2009 Member, The Cancer Prevention and Research Center, Washington State University  
 1993 Visiting Faculty, Glaxo-Wellcome, Inc., Pharmaceutical Research & Manufacturers Association Program

### RESEARCH AWARDS

- 1995 *Pharmacy Practice Research Award*, American Society of Health-Systems Pharmacists Research & Education Foundation  
 1995 *Pharmacotherapy Research Award*, American Society of Health-Systems Pharmacists Research & Education Foundation  
 1991 *Third Place, National Quality Scholars Competition*, Health Sciences Institute, Inc.

### SCHOLARLY HONORS

- 2016 Listed in *Who's Who in America*, 70<sup>th</sup> Edition  
 2001-present *Fellow*, American Society of Health-System Pharmacists  
 1997-present *Fellow*, American Society of Consultant Pharmacists  
 2000-2017 *Fellow*, American College of Forensic Examiners Institute  
 1996-2017 *Diplomate*, American Board of Forensic Medicine  
 2006-2008 Listed in *Who's Who in American Education*, 7<sup>th</sup> & 8<sup>th</sup> Editions  
 2006-2007 Listed in *Who's Who in American Women*, 25<sup>th</sup> Edition  
 2002-2007 Listed in *Who's Who in Medicine and Health Care*, 4<sup>th</sup> & 6<sup>th</sup> Editions  
 1999-2000 Listed in *Who's Who in the World*, 17th Edition  
 1998-1999 Listed in *Who's Who in the West*, 27th Edition  
 1997 Listed in *Outstanding Young Women of America*, 31st Edition  
 1992 Inducted in *Rho Chi* National Pharmacy Scholastic Honor Society

### TEACHING HONORS AND AWARDS

#### Washington State University

- 2003 Finalist, *Sahlin Faculty Excellence Award for Instruction*  
 2002 Finalist, *Sahlin Faculty Excellence Award for Instruction*  
 2001 Finalist, *Sahlin Faculty Excellence Award for Instruction*  
 2000 Finalist, *Sahlin Faculty Excellence Award for Instruction*  
 1999 Finalist, *Sahlin Faculty Excellence Award for Instruction*

#### Washington State University College of Pharmacy

- 1997 *Teacher of the Year Award*  
 1995 *Teacher of the Year Award*  
 1992 *Teacher of the Year Award*

### CERTIFICATIONS

Suicide Awareness and Referral Trainer, Washington State Pharmacy Association  
 Pharmacist-based Immunization Delivery, American Pharmacist Association  
 Mental Health First Aid for Adults and Youths, National Council for Behavioral Health  
 Adult and Pediatric CPR, AED & First Aid, American Red Cross

### LICENSURES

Pharmacist: California (#42733); Washington (#262-0301-13780); Idaho (#P7182)

### TEACHING EXPERIENCE [\* Instructor-of-Record]

#### Washington State University College of Pharmacy & College of Veterinary Medicine

- 2016-present Pharmacy 557: Pharmacotherapy V (guest lecturer)  
 2015-present Pharmacy 567\*: Public Health and Emergency Preparedness  
 2014-present Pharmacy 514: Pharmacotherapy I (guest lecturer)  
 2014-present Pharmacy 553: IPPE IV: Debrief (presentation grading)  
 2014-present Pharmacy 509: Professional Communications Lab (grading)  
 2012-2015 Pharmacy 599 Special Projects  
 2014-2015 Pharmacy 546\*: Selected Topics in Pharmacy Practice  
 2012-2013 Pharmacy 505\* Pharmacy Practice Foundations (course discontinued 2014)

2011-2013	Pharmacy 531 Applied Patient Care II
2011-2013	Pharmacy 541 Applied Patient Care III – Medication Therapy Management (facilitator)
2009-2013	Pharmacy 514* Pharmacotherapy I*
2008-2013	Pharmacy 507* Introduction to Therapeutic Agents - Top 200 Medications
2008-2013	Pharmacy 534 Pharmacotherapy II (guest lecturer)
2008-2013	Pharmacy 544 Pharmacotherapy III (guest lecturer)
2007-2011	Veterinary Medicine 502: Communication Skills (facilitator)
2000-2008	PharP 552* Pharmacotherapy I
2000-2006	PharP 450* Wellness & Preventive Medicine
1991-2000	PharP 538* Parenteral Products
1991-1999	PharP 551* Pharmacotherapy I
1991-1999	PharP 561 Acute Care Advanced Practice Experience
1991-1999	PharP 562 Ambulatory Care Advanced Practice Experience
1991-1999	PharP 563 Elective I Advanced Practice Experience*

### **WASHINGTON STATE UNIVERSITY SERVICE**

2015-present	Member, Campus Wellness Collaborative, Washington State University – Spokane
2014	Grant Reviewer, Alcohol and Drug Abuse Research Program
2014	Judge, Health Care Team Challenge Inter-professional Competition
2014	Member, College of Pharmacy Assessment Committee
2011-present	Member, College of Pharmacy Full Professors Committee
2008-present	Member, College of Pharmacy, Department of Pharmacotherapy Tenure & Promotion Committee
2012-2015	Faculty Senator, Washington State University
2011-2015	Grand Council Deputy, Kappa Psi Beta Pi Pharmaceutical Fraternity
2009-2013	Member, College of Pharmacy Student Progress Committee
2011-2013	Member, College of Pharmacy Transition Planning Committee
2010-2013	Member, College of Pharmacy Admissions Committee
2008-2011	Member, PYI Student Assessment Team
2006-2009	Member, College of Pharmacy Scholarship and Awards Committee
2007-2008	Member, Department of Pharmacotherapy Pullman Faculty Search Committee
2007-2008	Member, Department of Pharmacotherapy Pullman & Spokane Staff Search Committee
2006-2008	Member, College of Pharmacy Accreditation Review Steering Committee
2006-2008	Member, College of Pharmacy Accreditation Self-Study Standards for Faculty Committee
2004-2008	Coordinator, Gendering Research Across the Campuses (GRACe) Work-Life Issues and Policy Research Cluster
2006-2007	Chair, Association for Faculty Women Graduate Student Awards Committee
2005-2007	Member, Extramural Funding Committee, Gendering Research Across the Campuses
2003-2004	Member, University Task Force on Promotion & Tenure (Appointed by the Provost)
2003-2004	President, Association of Faculty Women
2001-2011	Washington State University Representative (Appointed by the President) Women in Higher Education Roundtable
2001	Co-Chair, College of Pharmacy Accreditation Retreat Committee
2000-2003	Member, University Committee on International Programs
1999-2003	Member, University Committee on Accreditation, Accountability & Assessment
1999-2003	Ex-Officio Member, College of Pharmacy Curriculum Committee
1999-2003	Member, College of Pharmacy Administrative Council
1998	Member, Student Health & Wellness Services Director Search Committee
1997-1998	Chairperson, College of Pharmacy Academic Standing Committee
1996-1997	Member, College of Pharmacy Admissions Committee
1995-1996	Chairperson, College of Pharmacy Academic Standing Committee
1993-1995	Member, College of Pharmacy Academic Standing Committee
1991-1999	Faculty Advisor, American Society of Health-System Pharmacists

### **COMMUNITY SERVICE**

2013-present	Member, Advisory Board, Fear-Free Veterinary Practices for Animals and their Humans
2007-2012	Volunteer, Northwest Doberman Rescue

1997-2005 Volunteer, Palouse Area Therapeutic Horsemanship Program for the Disabled

### **DOMESTIC & INTERNATIONAL SERVICE**

2005-2006 Member, Awards Committee, American College of Clinical Pharmacy  
 2001-2003 Contributing Scientist, Adherence to Long-Term Therapies Initiative, World Health Organization  
 2001-2003 Public Policy Liaison, Women's Health Practice & Research Network, American College of Clinical Pharmacy  
 2001-2003 Secretary / Treasurer, Pain Management Practice & Research Network, American College of Clinical Pharmacy  
 2001-2003 Member, Section of Teachers of Pharmacy Practice Awards Committee, American Association of Colleges of Pharmacy  
 2001-2003 Member, Reimbursement Task Force, College of Psychiatric & Neurologic Pharmacists  
 1999-2000 Member, Chronic Pain Management Task Force, Department of Labor & Industries of the State of Washington

### **PROFESSIONAL ASSOCIATIONS**

American Associations of Colleges of Pharmacy  
 American College of Clinical Pharmacy  
 American College of Forensic Examiners Institute  
 American Society of Consultant Pharmacists  
 American Society of Health-System Pharmacists  
*Kappa Psi* Pharmaceutical Fraternity [Grand Council Deputy Beta Pi Chapter 2012-2016]  
*Rho Chi* National Pharmacy Scholastic Honor Society  
 Washington State Pharmacy Association

### **EDITORIAL EXPERIENCE**

2017-present Editorial Board Member, *Clinical Drug Investigation*  
 2017 Reviewer, Pediatrics  
 2017 Reviewer, *Journal of Education, Society and Behavioural Science*  
 2017 Reviewer, *Pharmacotherapy*  
 2016-present Editorial Board Member, *Austin Pain & Relief*  
 2016 Reviewer, *Journal of Affective Disorders*  
 2016 Reviewer, American Journal of Managed Care  
 2015-present Editorial Board Member, *Journal of Musculoskeletal Disorders and Treatment*  
 2015-present Reviewer, *ClinicoEconomics and Outcomes Research*  
 2014-present Editorial Board Member, *Journal of Sleep Medicine and Disorders*  
 2014 Reviewer, *Journal of Addiction Medicine and Therapy*  
 2014-present Reviewer, *Pain Practice*  
 2014 Reviewer, *International Clinical Psychopharmacology*  
 2013-present Editorial Board Member, *Pain Studies and Treatment*  
 2011-2015 Reviewer, *Current Therapeutic Research*  
 2011-2015 Reviewer, *Clinical Drug Investigation*  
 2010 Commentator, *Evidence Based Medicine*, the British Medical Journal Group  
 2006 Reviewer, *Human Psychopharmacology Clinical and Experimental*  
 2004-2012 Editorial Board Member, *Clinical Therapeutics*  
 2001-present Reviewer, *Disease Management & Health Outcomes*  
 2001 Reviewer, *Pain Management for Primary Care Clinicians* [Textbook]  
 2001 Reviewer, *Journal of Rural Health*  
 1999-present Reviewer, *Drugs*  
 1999-2012 Reviewer, *American Journal of Managed Care*  
 1997-2012 Reviewer, *Journal of Health Care for the Poor & Underserved*  
 1997 Reviewer, *Journal of Clinical Pharmacy & Therapeutics*  
 1997-2007 Reviewer, *Medical Care*  
 1996-present Reviewer, *PharmacoEconomics*  
 1996 Reviewer, *1997 Nursing Drug Handbook* [Textbook]  
 1995-2010 Reviewer, *American Journal of Health-System Pharmacy*  
 1993-present Reviewer, *Clinical Therapeutics*

1993-2006	Editor, Perspectives on Pharmacotherapy, <i>The Female Patient</i>
1993-2006	Member, Editorial Board, <i>The Female Patient</i>
1993-1999	Editor, Pullman Memorial Hospital's <i>Pharm-Facts Newsletter</i>
1992-2004	Editorial Board Member, <i>Current Therapeutic Research</i>

### RESEARCH SUPPORT: Over \$3.2 Million [1990-present]

#### Extramural Research Support (Principal Investigator)

1. \$698,248 From National Institutes of Health (R34, PAR14-182). Mindfulness-Based Practices and Multiple Family Groups in Chronic Pain Patients with High Risk of Opioid Misuse. Principal Investigator: T.L. Skaer, BPharm, PharmD, Co-investigators: M.G. McDonnell, Ph.D., N.E., Morone, MD, C. Barbosa-Leiker, Ph.D. [2015 and 2016 submissions; not funded]
2. \$5,000 From Pullman Regional Hospital Community Impact Fellowship. Fostering Resiliency and Enhancing Patient Safety Via Programing Designed to Reduce Stress and Improve Health, Wellness, and Productivity. Principal Investigator: T.L. Skaer, BPharm, PharmD. [2016 submission; not funded]
3. \$664,812 From National Institutes of Health (R34, RFA-MH-16-410). Mindfulness-Based Stress Reduction, Social Medial, and Internet-Based Support for Anxiety and Depression in Pregnancy and Postpartum. Investigator: T.L. Skaer, BPharm, PharmD, Co-investigators: M. Wilson, Ph.D., MPH, M.R. Shaw, Ph.D., RN, C. Barbosa-Leiker, Ph.D., M.G. McDonnell, Ph.D. [2015 submission not funded]
4. \$118,297, from the Lupus Foundation of America. The Effects of Mental Health Comorbidities in Persons with SLE. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D; Co-Investigaor: M. DiBonaventura, Ph.D. [2012 and 2013 submissions; not funded]
5. \$90,211, from the National Alliance for Research on Schizophrenia and Depression, Pharmacologic Treatment Patterns Among Children and Adolescents with Depressive Illness: An Assessment of U.S. Office-Based Physician-Patient Encounters 1988-2002, and Comparison with Clinical Practice Guidelines from the American Academy of Child and Adolescent Psychiatry. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH. [2002-2006]
6. \$183,640, from the State of Washington, Office of the Attorney General (Vitamin Manufacturers Anti-Trust Settlement Fund), Can Phytoestrogens Improve Cognitive Function in Healthy Older Woman? Co-Principal Investigators: K.A. Beerman, Ph.D., T.L. Skaer, B.Pharm., Pharm.D.; Investigators: L.R. Fournier, D.A. Sclar, B.Pharm., Ph.D., M.K. McGuire, Ph.D., L.M. Robison, MSPH.[2002-2006]
7. \$125,370, from Janssen Pharmaceuticals, Inc., Phase II: Pharmacoepidemiology of Atypical Antipsychotics. Co-Principal Investigators: D.A. Sclar, B.Pharm., Ph.D., T.L. Skaer, B.Pharm., Pharm.D.; Investigators: C.L. DeVane, Pharm.D., J.S. Markowitz, Pharm.D., W.M. Dickson, B.Pharm., Ph.D., L.M. Robison, MSPH. [2003-2004]
8. \$22,020, from the National Network of Libraries of Medicine, Central Washington Resources and Education for Achieving Community Health (REACH). Co-Principal Investigators: S.K. McCord, MLIS, T.L. Skaer, B.Pharm., Pharm.D.; Investigator: V.F. Croft MSLS. [2002-2004]
9. \$12,000, from the United States Agency for International Development, Export Potential of Natural Medicinal Products from Malawi. Co-Principal Investigators: D.A. Sclar, B.Pharm., Ph.D., T.L. Skaer, B.Pharm., Pharm.D., L.M. Robison, MSPH, [2002]
10. \$96,360, from Janssen Pharmaceuticals, Inc., Pharmacoepidemiology of Atypical Antipsychotics. Co-Principal Investigators: D.A. Sclar, B.Pharm., Ph.D., T.L. Skaer, B.Pharm., Pharm.D.; Investigators: C.L. DeVane, Pharm.D., J.S. Markowitz, Pharm.D., W.M. Dickson, B.Pharm., Ph.D., L.M. Robison, MSPH.[2001-2002]
11. \$4,000, from Merck and Company / American Federation for Aging Research, Are Explicit Criteria for the Prescribing of Medications in the Elderly Utilized? An Assessment of Office-Based Physician-Patient Encounters in the United States 1990-1998. Principal Co-Investigators: T.L. Skaer, B.Pharm., Pharm.D., Y.C. Huckleberry, B.S., Pharm.D. (Scholarship in Geriatric Pharmacology). [2000]
12. \$61,782, from Bayer, Inc., Economic Appraisal of HMG-CoA Reductase Inhibitors. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH, Marc A. Evans, Ph.D. [2000-2001]
13. \$125,000, from Searle, Inc., Effect of Pharmaceutical Formulation for Antihypertensive Pharmacotherapy on Regimen Adherence and Health Service Expenditures. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH. [1996-1997]
14. \$160,900, from Glaxo Wellcome, Inc., Economic and Quality-of-Life Outcomes in the Treatment of Migraine. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH, R.F. Legg, B.Pharm., MBA, N.L. Nemece, M.D. [1996-1998]

15. \$150,000, from Pfizer, Inc., Economic Valuation of Amitriptyline, Desipramine, Nortriptyline, and Sertraline in the Management of Depression. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH, R.F. Legg, B.Pharm., MBA, N.L. Namec, M.D., R.S. Galin, M.D. [1994-1996]
16. \$5,000, from The Sigma Kappa Foundation, Adverse Medication Reaction Monitoring in Long-Term-Care. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH. [1994-1995]
17. \$25,000, from Boehringer Ingelheim Pharmaceuticals, Inc., Metered Dose Inhaler Technique and Quality-of-Life with Airways Disease: Assessing the Value of the Vitalograph in Educational Intervention. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: C.B. Wilson, B.Pharm., Pharm.D., D.A. Sclar, B.Pharm., Ph.D., T.A. Arnold, RRT, C.F. Garcia, RRT, L.N. Schmidt, CRTT, B.D. Key, B.Pharm., L.M. Robison, MSPH. [1994-1995]
18. \$48,605, from The Robert Wood Johnson Foundation, Cultural and Educational Determinants to the Use of Breast and Cervical Cancer Screening Among Hispanic Women. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH, G.H. Harding, M.D., MPH. [1993-1995]
19. \$130,000, from Hoechst Marion Roussel, Inc., Effect of Pharmaceutical Formulation of Diltiazem on Health Service Expenditures for Hypertension. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH, D.J. Markowski, Pharm.D., J.K.H. Won, Pharm.D. [1993-1995]
20. \$13,000, from The Diabetes Research & Education Foundation, Empowering the Diabetic Patient with Low Literacy: A Multi-Cultural Issue. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigators: D.A. Sclar, B.Pharm., Ph.D., L.M. Robison, MSPH. [1993-1994]
21. \$22,000, from Zeneca Pharmaceuticals, Inc., Applying Pharmacoeconomic and Quality-of-Life Measures to the Formulary Management Process. Principal Investigator: T.L. Skaer, B.Pharm., Pharm.D.; Co-Investigator: D.A. Sclar, B.Pharm., Ph.D. [1991-1992]

#### **Intramural Research Support**

1. \$11,000 From Washington State University Health Equities Seed Grant Program. *Pregnancy to Parenthood on Medication Assisted Treatment for Opioid Use*. Principal Investigator: C. Barbosa-Leiker; Role: Co-Investigator [2017-2018]
2. \$27,546 From Washington State University Alcohol and Drug Abuse Research Program *Multiple family groups, mindfulness and the management of chronic pain and high risk opioid use*. Co-Principal Investigators: D. Dyck, T.L. Skaer, B.Pharm., Pharm.D. [2013–2015]
3. \$8,000 From Washington State University's Office of Research. *Economic Issues in Mental Health Promotion and Their Effects on Public Policy*: Principal Investigator: L Hill, Ph.D., Co-Investigators: T.L. Skaer, B.Pharm., Pharm.D., L Parker, Ph.D., T. Power, Ph.D., R. Rosenman, Ph.D. [2007-2008]
4. \$2,250 From Washington State University's Gendering Research Across the Campuses (GRACe). *Gender and Academic Careers at Washington State University*. Principal Investigators: GRACe Work-Life Issues and Policy Research Cluster - T.L. Skaer, B.Pharm., Pharm.D., Cluster Coordinator. [2006-2007]
5. Course releases from the Washington State University Catalyzing the Future Grant Program, *Social Change, Gender Dynamics, and Inequities in Global Context: An Interdisciplinary Research Program*. Principal Investigators: Gendering Research Across the Campuses (GRACe) research group. Work-Life Issues and Policy Research Cluster Coordinator: T.L. Skaer, B.Pharm., Pharm.D. [2005-2006]
6. \$25,000, from the Washington State University Alcohol and Drug Abuse Research Program, *Fetal Alcohol Exposure in Swine: An Animal Model for Investigating the Effect of Alcohol on Aggression and Play Behavior*. Principal Co-Investigators: R.C. Newberry, Ph.D., T.L. Skaer, B.Pharm., Pharm.D. [2001-2003]

#### **Extramural Research Support (Co-Investigator)**

1. National Institutes of Health Pain Consortium, Centers of Excellence in Pain Education. Principal Investigator: University of Washington, Division of General Internal Medicine: WSU-based Consultant: T.L. Skaer, B.Pharm., Pharm.D. [2012-2013]
2. \$49,525, from the Washington State Department of Health, *Medication Assistance Partnership*. Co-Principal Investigators: G.D. Clifton, Pharm.D., D.A. Haberman, B.A.; Co-Investigators: M.A. Haberman, B.S.N., Ph.D., D.A. Sclar, B.Pharm., Ph.D., T.L. Skaer, B.Pharm., Pharm.D. [1999-2001]
3. \$112,000, from Forest Laboratories, Inc., *Economic Appraisal of Citalopram in the Treatment of Depression*. Principal Investigator: D.A. Sclar, B.Pharm., Ph.D.; Co-Investigators: T.L. Skaer, B.Pharm., Pharm.D., L.M. Robison, MSPH. [1997-2000]

4. \$267,325, from Zeneca Pharmaceuticals, Inc., *Effect of Health Education on Regimen Adherence and the Utilization of Health Maintenance Organization Services: A Prospective Trial Among Patients with Hypertension*. Principal Investigator: D.A. Sclar, B.Pharm., Ph.D.; Co-Investigators: T.L. Skaer, B.Pharm., Pharm.D., A.A. Chin, Pharm.D., M.P. Okamoto, Pharm.D., R.K. Nakahiro, Pharm.D., M.A. Gill, Pharm.D. [1990-1993]
5. \$247,000, from Boehringer Ingelheim Pharmaceuticals, Inc., *Utility of a Transdermal Delivery System for Antihypertensive Pharmacotherapy: Part I*. Principal Investigator: D.A. Sclar, B.Pharm., Ph.D.; Co-Investigators: T.L. Skaer, B.Pharm., Pharm.D., A. A. Chin, Pharm.D., M.P. Okamoto, Pharm.D., R.K. Nakahiro, Pharm.D., M.A. Gill, Pharm.D. [1990-1992]
6. \$150,000, from Hoechst Marion Roussel, Inc., *Effect of Pharmaceutical Formulation for Antihypertensive Pharmacotherapy on International Health Service Expenditures: Part I*. Principal Investigator: D.A. Sclar, B.Pharm., Ph.D.; Co-Investigators: T.L. Skaer, B.Pharm., Pharm.D., L.M. Robison, MSPH. [1993-1995]

#### **Extramural Support for Educational Innovation**

1. \$70,000, from Boehringer Ingelheim Pharmaceuticals, Inc., to support the *Residency & Fellowship Programs in Ambulatory Care* at Pullman Memorial Hospital. Director: T.L. Skaer, B.Pharm., Pharm.D. [1992-1995]
2. \$105,000, from Clintec Nutrition, Inc., equipment contribution to the *Parenteral Products Laboratory*, Instructor of Record: T.L. Skaer, B.Pharm., Pharm.D. [1992]

#### **Extramural and Intramural Support for Doctor of Pharmacy Students (Faculty Advisor)**

1. \$4,000 From Washington State University Alcohol and Drug Abuse Research Program: Undergraduate Research Fellowship. *Complementary and Alternative Medicine Use Among Chronic Pain Patients*. Student: A.L. Male Ervik, Pharm.D. Candidate 2015; Faculty Advisor: T.L. Skaer, B.Pharm., Pharm.D. [2013-2015]
2. \$4,000 From Washington State University Alcohol and Drug Abuse Research Program: Undergraduate Research Fellowship. Management of Chronic Pain in Patients with High Risk Opioid Use Through Narcotic Education. Student: A. Nwude, Pharm.D. Candidate 2015; Faculty Advisor: T.L. Skaer, B.Pharm., Pharm.D. [2013-2015]
3. \$3,500 from Target Inc, Local Community Outreach: Providing Influenza Vaccinations Via Kappa Psi Beta Pi Pharmaceutical Fraternity. Faculty Advisor: T.L. Skaer, B.Pharm., Pharm.D. [2013-2014]
4. \$3,000 from Target, Inc., Local Community Outreach; Health fairs and Influenza Vaccinations Via Kappa Psi Beta Pi Pharmaceutical Fraternity. Faculty Advisor: T.L. Skaer, B.Pharm., Pharm.D. [2012-2013]

#### **PUBLICATIONS**

[Google Scholar](#): Cited 2,813 times h-index 29, i10-index 63; 2012-present 645 citations h-index 14, i10-index 18.

[Research Gate](#): RG Score 37.72 (95<sup>th</sup> percentile); h-index 27

#### **Peer-Reviewed Original Research Articles**

1. Lederhos-Smith C, Skaer TL, Orr M, Barbosa-Leiker C, Howell DN, Dyck DG. Development of a Multi-family Group and Mindfulness Treatment for Chronic Pain: Preliminary Outcomes. *J Musculoskel Disord Treatment* 2017;3(4):open access.
2. Skaer TL, Helmann AC, Ward E. Facial Itching Associated with Missed Doses of Vilazodone. *Intl J Medical Pharmaceut Case Reports* 2016;7(3):1-5.
3. Sclar DA, Evans MA, Skaer TL, Robison LM, Chung KC, Li-McLeod J, Poulos NS. Alpha1 Proteinase Inhibitor (Human) in the Treatment of Hereditary Emphysema Secondary to Alpha1-Antitrypsin Deficiency: Effect on Years of Life Gained. *Clin Drug Invest* 2012;32(5):353-60. [Cited 9 times]
4. Wilson M, Neumiller JJ, Sclar DA, Robison LM, Skaer TL. Ethnicity/Race, Use of Pharmacotherapy, Scope of Physician Ordered Cholesterol Screening, and Provision of Diet/Nutrition or Exercise Counseling During U.S. Office-Based Visits by Patients with Hyperlipidemia. *Am J Cardiovasc Drugs* 2010;10(2):105-8. [Cited 8 times]
5. Neumiller JJ, Sclar DA, Robison LM, Maldonado AL, Setter SM, Skaer TL. Ethnicity/Race and the Extent of Physician-Ordered Hemoglobin A1C During US Office-Based Visits by Patients with Diabetes Mellitus. *Diabetes Educ* 2010;36(1):65-8. [Cited 1 time]
6. Skaer TL. Increased Antidepressant and Antipsychotic use in the USA Between 1996 and 2005 [Comment on: Olfson M, Marcus SC. National Patterns in Antidepressant and Antipsychotic Use in the USA. *Arch Gen Psychiatry* 2009 229;66(8):848-56]. *Evid Based Ment Health* 2010;13:62.
7. Sclar DA, Robison LR, Skaer TL. Does Comorbid Mental Illness Influence the Treatment of Depression Among Children and Adolescents in the United States? *Dis Manage Health Outcomes* 2009;17:257-64.

8. Neumiller JJ, Sclar DA, Robison LM, Setter SM, Skaer TL. Prevalence of Depression and Use of Antidepressant Pharmacotherapy Among Ambulatory Patients with Diabetes Mellitus in the United States. *Curr Ther Res* 2009;70(6):472-6. [Cited 3 times]
9. Neumiller JJ, Sclar DA, Robison LM, Setter SM, Skaer TL. Rate of Obesity in U.S. Ambulatory Patients with Diabetes Mellitus: A National Assessment of Office-Based Physician Visits. *Primary Care Diabetes* 2009;3(3):197-9.
10. Skaer TL, Sclar DA, Robison LM. Trends in Prescriptions for Antidepressant Pharmacotherapy among US Children and Adolescents Diagnosed with Depression, 1990 through 2001: An Assessment of Accordance with Recommendations from the American Academy of Child and Adolescent Psychiatry. *Clin Ther* 2009;31 (Pt1):1478-87. [Cited 33 times]
11. Sclar DA, Robison LM, Skaer TL. Ethnicity/race and the Diagnosis of Depression and the Use of Antidepressants by Adults in the United States. *Intl Clin Psychopharmacol* 2008;23(2):106-9. [Cited 46 times]
12. Sclar DA, Gavrun C, Robison LM, Skaer TL. Hospital Length of Stay for Children and Adolescents Diagnosed with Depression: Is Primary Payer an Influencing Factor? *Gen Hosp Psychiatry* 2008;30(1):73-6. [Cited 14 times]
13. Skaer TL, Sclar DA, Robison LM. Trend in Anxiety Disorders in the United States 1990-2003. *Primary Care Comm Psychiatry* 2008;13(1):1-7. [Cited 4 times]
14. Sclar DA, Robison LM, Skaer TL. Concomitant Triptan and SSRI or SNRI Use: A Risk for Serotonin Syndrome. Headache: *J Head Face Pain* 2008;48(1):126-9. [Cited 20 times]
15. Fournier LR, Ryan-Borchers TA, Robison LM, Wiediger MA, Park JS, Chew BP, McGuire MK, Sclar DA, Skaer TL, Beerman KA. The Effects of Soy Milk and Soy Isoflavone Supplements on Cognitive Performance in Healthy Postmenopausal Women. *J Nutr Health Aging* 2007;11(2):155-64. [Cited 86 times]
16. Cloutier S, Skaer TL, Newberry RC. Consumption of Alcohol by Sows in a Choice Test. *Physiol Behav* 2006;88:101-7. [Cited 4 times]
17. Skaer TL, Sclar DA, Robison LM. Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States 1990-2001. Does Type of Insurance Influence Access to Innovation? *Diabetes Educ* 2006;32(6):940-53. [Cited 10 times]
18. Sclar DA, Evans MA, White JR, Skaer TL, Robison LM. Economics of basal insulin added to oral agents versus twice-daily premixed insulin as initial therapy for type 2 diabetes. *Diabetologia* 2005;48:A335. [Cited 3 times]
19. Sclar DA, Evans MA, Skaer TL, Robison LM, Chung KC, Poulos NS. Economic and Epidemiologic Modeling of Full-Length Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM), in Previously Treated Patients with Hemophilia A. Comparison with B-Domain Deleted rFVIII (BDDrFVIII), and Utility of Potential Viral Transmission Reduction Due to Plasma/Albumin-Free Status. *Drugs Res Develop* 2005;6(3):149-56. [Cited 3 times]
20. Robison LM, Sclar DA, Skaer TL. Datapoints: Trends in ADHD and Stimulant Use among U.S. Adults: 1995-2002. *Psychiatric Services* 2005;56(12):1497. [Cited 28 times]
21. Robison LM, Skaer TL, Sclar DA. Is Attention-Deficit Hyperactivity Disorder Diagnosed in Adults? An Examination of U.S. Office-Based Physician Visits, 1995-2000. *Intl J Pharmaceut Med* 2004;18(6):337-41. [Cited 5 times]
22. Skaer TL, Sclar DA, Robison LM. Antidepressant Trends Among Children and Adolescents Diagnosed with Depression: 1990-2001. *J Child Adolesc Psychopharmacol* 2004;14(4):528-9. [Cited 4 times]
23. Robison LM, Sclar DA, Skaer TL, Galin RS. Treatment Modalities Among U.S. Children Diagnosed with Attention-Deficit/Hyperactivity Disorder: 1995 - 1999. *Intl Clin Psychopharmacol* 2004;19(1):17-2. [Cited 39 times]
24. Robison LM, Skaer TL, Sclar DA, Galin RS. Is Attention-Deficit / Hyperactivity Disorder Increasing Among Girls in the U.S.? Trends in Diagnosis and the Prescribing of Stimulants. *CNS Drugs* 2002;16(2):129-37. [Cited 153 times]
25. Skaer TL, Sclar DA, Evans MA, Mukherjee SK, Robison LM. HMG-CoA Reductase Inhibitors in Secondary Prevention of Coronary Heart Disease: Comparison of Expense per Year of Life Gained. *Am J Cardiol* 2001;87(Suppl R):21-5.
26. Skaer TL, Sclar DA, Robison LM. Complaint of Insomnia in the United States 1995-1998: Prevalence, Psychiatric Comorbidity, and Pharmacologic Treatment Patterns. *Prim Care Psychiatry* 2001;7(4):145-51. [Cited 8 times]
27. Skaer TL, Sclar DA, Robison LM, Galin RS. Trends in the Rate of Self-Report and Diagnosis of Erectile Dysfunction in the United States 1990-1998. Was the Introduction of Sildenafil an Influencing Factor? *Dis Manage Health Outcomes* 2001;9(1):33-1. [Cited 8 times]



28. Skaer TL, Sclar DA, Robison LM, Galin RS. Trends in the Rate of Depressive Illness and Use of Antidepressive Pharmacotherapy by Ethnicity / Race. An Assessment of Office-Based Visits in the United States, 1992-1997. *Clin Ther* 2000;22(12):1575-89. [Cited 96 times]
29. Skaer TL, Sclar DA, Robison LM, Galin RS. Trend in the Use of Antidepressant Pharmacotherapy and Diagnosis of Depression in the USA: An Assessment of Office-Based Visits 1990 to 1998. *CNS Drugs* 2000;14(6):473-81. [Cited 25 times]
30. Ballasiotes AA, Skaer TL. Use of Lamotrigine in a Patient with Bipolar Disorder and Psychiatric Comorbidity. *Clin Ther* 2000;22(9):1146-8. [Cited 7 times]
31. Skaer TL, Robison LM, Sclar DA, Galin RS. Anxiety Disorders in the USA, 1990 to 1997: Trend in Complaint, Diagnosis, Use of Pharmacotherapy, and Diagnosis of Comorbid Depression. *Clin Drug Invest* 2000;20(4):255-65. [Cited 23 times]
32. Skaer TL, Robison LM, Sclar DA, Galin RS. Treatment of Depressive Illness Among Children and Adolescents in the United States. *Curr Ther Res* 2000;61(10):692-705. [Cited 9 times]
33. Sclar DA, Skaer TL, Robison LM, Galin RS. Economic Appraisal of Citalopram in the Management of Single-Episode Depression. *J Clin Psychopharmacol* 1999;19(Suppl 1):47S-54S. [Cited 21 times]
34. Sclar DA, Robison LM, Skaer TL, Galin RS. Hospital Length of Stay for Schizophrenia: Is Primary Payer an Influencing Factor? *Dis Manage Health Outcomes* 1999;5(6):339-47. [Cited 1 time]
35. Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: The Influence of Age, Gender, and Race. *Diabetes Educ* 1999;25(4):531-8. [Cited 54 times]
36. Skaer TL, Robison LM, Sclar DA, Galin RS. Psychiatric Comorbidity and Pharmacological Treatment Patterns Among Patients Presenting with Insomnia: An Assessment of Office-Based Encounters in the USA in 1995 and 1996. *Clinical Drug Investigation* 1999;18(2):161-167. [Cited 21 times]
37. Robison LM, Sclar DA, Skaer TL. Attention-Deficit / Hyperactivity Disorder. *N Engl J Med* 1999;340(22):1767. [Cited 8 times]
38. Sclar DA, Robison LM, Skaer TL, Galin RS. Depression in Diabetes Mellitus: A National Survey of Office-Based Encounters, 1990-1995. *Diabetes Educ* 1999;25(3):331-40. [Cited 14 times]
39. Robison LM, Sclar DA, Skaer TL, Galin RS. National Trends in the Prevalence of Attention-Deficit / Hyperactivity Disorder and the Prescribing of Methylphenidate Among School-Age Children: 1990-1995. *Clin Pediatr* 1999;38(4):209-17. [3rd most cited article for this journal 2011-2013; cited 273 times]
40. Sclar DA, Robison LM, Skaer TL, Galin RS. Ethnicity and the Prescribing of Antidepressant Pharmacotherapy: 1992-1995. *Harv Rev Psychiatry* 1999;7(1):29-36. [Cited 69 times]
41. Skaer TL, Robison LM, Sclar DA, Dickson WM, Kozma CM, Reeder CE. Use of Antidepressant Pharmacotherapy Within the First Year After Diagnosis of Diabetes Mellitus: A Study of a Medicaid Population. *Curr Therap Res* 1999;60(8):415-22. [Cited 6 times]
42. Sclar DA, Robison LM, Skaer TL, Galin RS. Depression in Parkinson's Disease: A National Survey of Office-Based Visits 1990-1995. *Intl J Geriatr Psychopharmacol* 1998;1(4):216-19. [Cited 5 times]
43. Sclar DA, Robison LM, Skaer TL, Galin RS. What Factors Influence the Prescribing of Antidepressant Pharmacotherapy? An Assessment of National Office-Based Encounters. *Intl J Psychiatry Med* 1998;28(4):407-19. [Cited 51 times]
44. Sclar DA, Skaer TL, Robison LM, Galin RS. Trends in the Prescribing of Antidepressant Pharmacotherapy: Office-Based Visits, 1990-1995. *Clin Ther* 1998;20(4):871-84. [Cited 58 times]
45. Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Antidepressant Prescribing Patterns: A Comparison of Blacks and Whites in a Medicaid Population. *Clin Drug Invest* 1998;16(2):135-40. [Cited 25 times]
46. Sclar DA, Skaer TL, Robison LM, Galin RS, Legg RF, Nemec NL. Economic Outcomes with Antidepressant Pharmacotherapy: A Retrospective Intent-to-Treat Analysis. *J Clin Psychiatry* 1998;59(Suppl 2):13-17. [Cited 30 times]
47. Skaer TL, Robison LM, Sclar DA, Harding GH. Breast Cancer Mortality Declining But Screening Among Subpopulations Lags. *Am J Public Health* 1998;88(2):307-8. [Cited 11 times]
48. Sclar DA, Robison LM, Skaer TL, Terriff CM, Garrison MW. International Expenditure Projections for Pharmacotherapeutic Advances in the Treatment of HIV / AIDS. *Clin Ther* 1997;19(1):86-95. [Cited 3 times]
49. Sclar DA, Skaer TL, Robison LM, Galin RS, Legg RF, Nemec NL. Evidence-Based Algorithm for Antidepressant Pharmacotherapy. *JAMA: Southeast Asian Edition* 1997;277(Suppl 13-1):33-40.

50. Puder KL, Wood LL, Sherrill A, Sclar DA, Robison L, Skaer TL, Galin RS, Legg RF, Nemec NL. Health Economics with Retrospective Date: Selection Bias Issues. *J Intl Med Res* 1997;25(1):45-51. [Cited 3 times]
51. Skaer TL, Sclar DA, Robison LM, Legg RF, Galin RS, Nemec NL. Antidepressant Pharmacotherapy: Effect on Women's Resource Utilization Within a Health Maintenance Organization. *J Applied Therapeutics* 1996;2(1):45-52. [Cited 13 times]
52. Skaer TL, Robison LM, Sclar DA, Harding GH. Utilization of Curanderos Among Foreign Born Mexican-American Women Attending Migrant Health Clinics. *J Cultural Diversity* 1996;3(2):29-34. [Cited 33 times]
53. Skaer TL, Robison LM, Sclar DA, Harding GH. Financial Incentive and the Use of Mammography Among Hispanic Migrants to the United States. *Health Care Women Intl* 1996;17(4):281-291. [Selected for a 2012 systematic research project entitled, Effectiveness of Intervention to Enhance Cultural Competence, Appropriateness, and Safety of Health and Mental Health Services. Funded by Canadian Institutes of Health Research] [Cited 38 times]
54. Skaer TL, Wilson CB, Sclar DA, Arnold TA, Garcia CF, Schmidt LM, Key BD, Robison LM. Metered-Dose Inhaler Technique and Quality of Life with Airways Disease: Assessing the Value of the Vitalograph in Educational Intervention. *J Intl Med Res* 1996;24(4):369-75. [Cited 16 times]
55. Skaer TL, Robison LM, Sclar DA, Harding GH. Cancer Screening Determinants Among Hispanic Women Using Migrant Health Clinics. *J Health Care Poor Underserved* 1996;7(4):338-54. [Cited 76 times]
56. Sclar DA, Robison LM, Skaer TL, For the Over-the-Counter Medication Intervention Project Team. Pharmacy Consultation and Over-the-Counter Medication Purchasing Outcomes. *J Clin Pharm Ther* 1996;21(3):177-84. [Cited 34 times]
57. Skaer TL, Robison LM, Sclar DA, Harding GH. Knowledge, Attitudes, and Patterns of Cancer Screening: A Self-Report Among Foreign Born Hispanic Woman Utilizing Rural Migrant Health Clinics. *J Rural Health* 1996;12(3):169-77. [Cited 47 times]
58. Sclar DA, Robison LM, Maheu AA, Skaer TL. Prescribing Rationale and Budgetary Outcomes Associated with the Introduction of a Combined Formulation of Diclofenac Sodium and Misoprostol in Canada. *J Intl Med Res* 1995;23(6):439-48. [Cited 4 times]
59. Sclar DA, Robison LM, Skaer TL, Galin RS, Legg RF, Nemec NL, Hughes TE, Buesching DP, Morgan M. Antidepressant Pharmacotherapy: Economic Valuation of Fluoxetine, Paroxetine, and Sertraline in a Health Maintenance Organization. *J Intl Med Res* 1995;23(6):395-12. [Cited 105 times]
60. Skaer TL, Sclar DA, Robison LM, Galin RS, Legg RF, Nemec NL. Economic Valuation of Amitriptyline, Desipramine, Nortriptyline, and Sertraline in the Management of Patients with Depression. *Curr Ther Res* 1995;56(6):556-567. [Cited 56 times]
61. Sclar DA, Legg RF, Skaer TL, Robison LM, Nemec NL. Ipratropium Bromide in the Management of Chronic Obstructive Pulmonary Disease: Effect on Health Service Expenditures. *Clin Ther* 1994;16(3):595-601. [Cited 14 times].
62. Sclar DA, Tessier GC, Skaer TL, Legg RF, Robison LM, Nemec NL. Effect of Pharmaceutical Formulation of the Utilization of Medicaid and Health Maintenance Organization Services. *Curr Ther Res* 1994;55(10):1136-49. [Cited 6 times]
63. Sclar DA, Skaer TL, Robison LM, Legg RF, Nemec NL. Antihypertensive Pharmacotherapy: Economic Outcomes in a Health Maintenance Organization. *Curr Ther Res* 1994;55(9):1056-66. [Cited 7 times]
64. Sclar DA, Robison LM, Skaer TL, Legg RF, Nemec NL, Galin RS, Hughes TE, Buesching DP. Antidepressant Pharmacotherapy: Economic Outcomes in a Health Maintenance Organization. *Clin Ther* 1994;16(4):715-30. [Cited 140 times]
65. Skaer TL, Sclar DA, Robison LM, Chin A, Gill MA, Okamoto MP, Nakahiro RK. Effect of pharmaceutical Formulation on Health Service Utilization: A Retrospective Evaluation in a Medicaid Population. *Clin Ther* 1993;15(4):715-25. [Cited 23 times]
66. Day RD, Jinks MJ, Skaer TL, Ismail R, Trisdikoon P. Family Planning and AIDS/HIV Intervention from a Cross-Cultural Perspective: Enhancing the Pharmacist's Role. *Am J Pharmaceut Educ* 1993;57(3):221-29.
67. Skaer TL, Sclar DA, Robison LM, Markowski DJ, Won JKH. Effect of Pharmaceutical Formulation for Diltiazem on Health Care Expenditures for Hypertension. *Clin Ther* 1993;15(5):905-11. [Cited 22 times. Featured in: *Inpharma Weekly* 1993;1.6]
68. Sclar DA, Skaer TL, Robison LM, Cin A, Okamoto MP, Nakahiro RK, Gill MA. Effect of antihypertensive formulation on health service expenditures. *Clin Auton Res* 1993;3(6):363-68. [Cited 7 times]
69. Skaer TL, Sclar DA, Markowski DJ, Won JKH. Effect of Value-Added Utilities on Prescription Refill Compliance and Health Care Expenditures for Hypertension. *J Hum Hypertens* 1993;7(5):515-18. [Cited 61 times]

70. Skaer TL, Sclar DA, Markowski DJ, Won JKH. *Effect of Academic Detailing on the Utilization of Intravenous Antimicrobial Therapy. Curr Ther Res* 1993;53(4):349-55. [Cited 1 time]
71. Beal JF, Skaer TL, Day RD, Jinks MJ. The Comfort Level of Pharmacists Who Counsel Contraceptive Patients. *J Clin Pharm Ther* 1993;18(6):317-24.
72. Skaer TL, Sclar DA, Markowski DJ, Won JKH. Utility of a Sustained-Release Formulation for Antihypertensive Therapy. *J Hum Hypertens* 1993;7(5):519-22. [Cited 16 times]
73. Skaer TL, Sclar DA, Markowski DJ, Won JKH. Effect of Value-Added Utilities in Promoting Prescription Refill Compliance Among Patients with Hypertension. *Curr Ther Res* 1993;53(3):251-55. [Cited 12 times]
74. Skaer TL, Sclar DA, Markowski DJ, Won, JKH. Effect of Value-Added Utilities on Prescription Refill Compliance and Medicaid Health Care Expenditures: A Study of Patients with Non-Insulin-Dependent Diabetes Mellitus. *J Clin Pharm Ther* 1993;18(4):295-99. [Cited 93 times]
75. Skaer TL, Sclar DA, Robison LM, Markowski DJ, Won JKH. Effect of Pharmaceutical Formulation on Health Care Expenditures for Hypertension: A Study of Verapamil in a Medicaid Population. *Curr Ther Res* 1993;53(3):256-64 [Cited 6 times]
76. Sclar DA, Skaer TL, Chin A, Okamoto MP, Nakahiro RK, Gill MA. Effect of Health Education on the Utilization of HMO Services: A Prospective Trial Among Patients with Hypertension. *Drug Topics: Primary Cardiology* 1992;18(Suppl 1):30-35. [Cited 17 times]
77. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of Health Education on the Utilization of Antihypertensive Therapy: A Prospective Trial Among HMO Enrollees. *Drug Topics: Primary Cardiology* 1992;18(Suppl 1):24-29. [Cited 15 times]
78. Sclar DA, Skaer TL, Chin A, Okamoto MP, Gill MA. Cost-Effectiveness of Transdermal Clonidine. *Cardiology* 1991;5(Suppl 2):37-40.
79. Sclar DA, Skaer TL. Effect of Medication Utilization Review on Medicaid Health Service Expenditures: A Case Study of Patients with Non-Insulin Dependent Diabetes Mellitus. *J Res Pharmaceutical Econ* 1991;3(1):75-89. [Cited 9 times]
80. Sclar DA, Skaer TL, Chin A, Okamoto MP, Nakahiro RK, Gill MA. Effectiveness of the C-Cap™ in Promoting Prescription Refill Compliance Among Patients with Glaucoma. *Clin Ther* 1991;13(3):396-400. [Cited 23 times since publication]
81. Sclar DA, Skaer TL, Chin A, Okamoto MP, Gill MA. Utility of a Transdermal Delivery System for Antihypertensive Therapy: Part II. *Am J Med* 1991;91(Suppl 1A):57S-60S. [Cited 30 times]
82. Sclar DA, Skaer TL, Chin A, Okamoto MP, Gill MA. Utility of a Transdermal Delivery System for Antihypertensive Therapy: Part I. *Am J Med* 1991;91(Suppl 1A):50S-56S. [Cited 23 times]
83. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of Health Education in Promoting Prescription Refill Compliance Among Patients with Hypertension. *Clin Ther* 1991;13(4):489-95. [Cited 115 times]

#### Other Peer-Reviewed Scholarly Works

1. Skaer TL. Current Issues Regarding the Care of the Fibromyalgia Patient. *Fibrom Open Access*. 2017;2:120.
2. Skaer TL, Kwong J. Illness Perceptions and Burden of Disease in Fibromyalgia. *Exp Rev Pharmacoecon Outcomes Res*. 2017;17(1):9-15. [IF 1.631] Published online 12/20/2016
3. Skaer TL. Treatment Recommendations for Fibromyalgia. *Intl J Pharma Res Rev*. 2016;5(4):19-28. [GIF 0.675] [Cited 1 time]
4. Skaer TL, Nwude AC. Opioid Prescribing Laws and Emergency Department Guidelines for Chronic Non-Cancer Pain in Washington State. *Pain Pract*. 2016;16(5):642-647. [IF 2.495] Published online 09/15/2015 [Cited 2 times]
5. Skaer TL Research Findings Using Mindfulness-Based Interventions for Chronic Pain. *Pain Studies and Treatment*. 2015;3(4):38-45. [Cited 1 time]
6. Skaer TL, Male Ervik AL, Nwude A. Mindfulness-Based Therapy for Chronic Insomnia. *J Sleep Med Disord*. 2014;1(2):1007.
7. Skaer TL, Nwude A, Male Ervik AL. Sleep Disturbance and Suicide Risk in the Elderly. *J Sleep Disord Ther*. 2014;3(5):181.
8. Skaer TL. Dosing Considerations with Transdermal Formulations of Fentanyl and Buprenorphine for the Treatment of Cancer Pain. *J Pain Res*. 2014;7:495-503. Online Open Access: [Cited 8; Accessed 5,177 times, Downloaded 1,838 times]
9. Leonard J, Skaer TL, Garrison M. Can Flush and Lock Solutions Used in Human Medicine Be Applied to Large Animal IV Therapy: A Systematic Review. *J Equine Vet Sci*. 2014;37(7):837-841.

10. Skaer TL. Fibromyalgia: Disease Synopsis, Medication Cost-Effectiveness, and Economic Burden. *PharmacoEconomics*. 2014;32(5):457-66. [available online and in press] [Cited 27 times]
11. Sclar DA, Robison LM, Skaer TL, et al. Concomitant Use of a Triptan and SSRI or SNRI After the US Food and Drug Administration Alert on Serotonin Syndrome. *Headache*. 2012;52(2):198-203. [Cited 20 times]
12. Skaer TL, Sclar DA. Economic Implications of Sleep Disorders. *PharmacoEconomics*. 2010;11:1015-1023. [Cited 36 times]
13. Sclar DA, Robison LM, Gavrun CA, Skaer TL. Authors' response to Letter to the Editor, [re: Sclar DA, Robison LM, Gavrun CA, Skaer TL. Hospital Length of Stay for Children and Adolescents Diagnosed with Depression: is Primary Payer an Influencing Factor? *Gen Hosp Psychiatry* 2010;3(2):23:229-30.
14. Skaer TL, Use of Transdermal Opioids for Cancer Pain. *Health Quality Life Outcomes*. 2006;4(24):1-15. Open access journal: <http://www.hqlo.com/content/4/1/24> "Highly accessed" [Cited 50 times]
15. Skaer TL, Sclar DA. Anxiety Disorders in Women Part 2: Pharmacotherapy. *The Female Patient*. 2006;31(8):23-28.
16. Skaer TL, Sclar DA. Anxiety Disorders in Women Part 1: Prevalence, Trends, and Psychotherapy. *The Female Patient*. 2006;31(7):20-27. [Cited 1 time]
17. Skaer TL. Practice Guidelines for Transdermal Opioids in Malignant Pain. *Drugs*. 2004,64(23): 2629-2638. [Cited 65 times]
18. Skaer TL. Depression and Antidepressant Use Escalating in the US. *Pharmacoeconomics & Outcomes News*. 2001;299:10.
19. Richwald GA, Skaer TL. New Approaches to the Management of External Genital Warts in the Female Patient. *The Female Patient: OB GYN Edition*. 2001;26(11):50-56.
20. Richwald GA, Skaer TL. New Approaches to the Management of External Genital Warts in the Female Patient. *The Female Patient: Primary Care Edition*. 2001;26(11):17-24.
21. Skaer TL. First-line TCA therapy common in children and adolescents. *PharmacoEconomics & Outcomes News*. 2001;290:25.
22. Skaer TL, Robison LM, Sclar DA. Depression and Insomnia: Interrelationship and Treatment. *Econ Neurosci* 2000;2(10):60-65.
23. Skaer TL, Robison LM, Sclar DA. Diagnosis and Treatment of Depression in the Diabetic Patient. *Econ Neurosci*. 2000;2(9):63-68.
24. Skaer TL, Sclar DA, Robison LM, Galin RS. The Need for an Iterative Process for Assessing Economic Outcomes Associated with Selective Serotonin Reuptake Inhibitors. *PharmacoEconomics*. 2000;18(3):205-214. [Cited 5 times]
25. Skaer TL, Robison LM, Sclar DA. Diagnosis and Treatment of Depression in the Cancer Patient. *Oncology Econ*. 2000;1(5):62-69. [Cited 2 times]
26. Skaer TL. Anxiety Disorders in the US: 'Major Public Health Concern' *PharmacoEconomics & Outcomes News*. 2000;292:1.6.
27. Skaer TL. Insomnia Pharmacotherapy: Selecting a Hypnotic Agent. *Pharmacy & Therapeutics*. 2000;25(2):93-102. [Cited 2 times]
28. Sclar DA, Skaer TL, Robison LM. Antidepressant Pharmacotherapy: A Review of Pharmacoeconomic Research. *L'Encéphale*. 1999;25(5):373-380.
29. Skaer TL. Insomnia and Depression in the Female Patient. *The Female Patient*. 1999;24(10):58-65.
30. Sclar DA, Robison LM, Skaer TL, Galin RS. Is Depression Underdiagnosed and Antidepressant Pharmacotherapy Underutilized in Patients with Diabetes Mellitus? *Econ Neurosci*. 1999;1(1):49-51.
31. Sclar DA, Skaer TL, Robison LM, Stowers JK. Economic Appraisal of Antidepressant Pharmacotherapy. Critical Review of the Literature and Future Directions. *Depress Anxiety*. 1998;8(Suppl 1):121-127. [Cited 12 times]
32. Skaer TL. Cancer Pain Management. *Am J Pharmaceut Ed*. 1998;62(3):182-189. [Cited 2 times]
33. Campbell LK, Robison LM, Skaer TL, Sclar DA. Depression: Interventions and Their Effectiveness. *Dis Manage Health Outcomes* 1997;2(5):223-237. [Cited 11 times]
34. Skaer TL. Clinical Presentation and Treatment of Migraine. *Clin Ther* 1996;18(2):229-245. [Cited 30 times]
35. Skaer TL, Sclar DA, Robison LM. Noncompliance with Antihypertensive Therapy: Economic Consequences. *PharmacoEconomics*. 1996;9(1):1-4. [Cited 24 times]
36. Skaer TL. Therapeutic Use of Sumatriptan in the Treatment of Migraine. *The Female Patient*. 1995;20(7):12-16.
37. Skaer TL. Prevention and Treatment of Osteoporosis. *Pharm Ther*. 1995;20(2):88-102.
38. Skaer TL. Management of Pain in the Cancer Patient. *Clin Ther*. 1993;15(4):638-649. [Cited 16 times]

39. Skaer TL. Systemic Lupus Erythematosus: Characteristics and Treatment. *The Female Patient*. 1993;18(9):35-41.
40. Skaer TL. Total Parenteral Nutrition: Clinical Considerations. *Clin Ther*. 1993;15(2):272-282. [Cited 3 times]
41. Skaer TL. Applying Pharmacoeconomic and Quality-of-Life Measures to the Formulary Management Process. *Hosp Formulary*. 1993;28(6):577-584. [Cited 13 times]
42. Skaer TL. Parenteral Nutrition: Clinical Assessment and Product Preparation. *Am J Pharmaceut Ed*. 1993;57(3):162-167. [Cited 4 times]
43. Skaer TL. Medication-Induced Systemic Lupus Erythematosus. *Clin Ther*. 1992;14(4):496-506. [Cited 34 times]
44. Sclar DA, Skaer TL. Pharmaceutical Formulation and Healthcare Expenditures. *PharmacoEconomics*. 1992;2(4):267-269. [Cited 10 times]
45. Sclar DA, Skaer TL. Current Concepts in the Treatment of Alzheimer's Disease. *Clin Ther*. 1992;14(1):2-10. [Cited 6 times]
46. Skaer TL. Dosing Considerations in the Pediatric Patient. *Clin Ther*. 1991;13(5):526-544. [Cited 25 times]
47. Richards VR, Skaer TL\*. Development of a Pharmacy Home Care Program. *Topics Hospital Pharm Manage*. 1988;8(3):55-66.

#### Peer-Reviewed Technical Articles

1. Skaer TL, Williams LA. Basic Bibliography: Biotechnology Pharmacoeconomics Part I. *Hospital Pharm*. 1994;29(11):1053-1054.
2. Skaer TL, Williams LA. Basic Bibliography: Biotechnology Pharmacoeconomics Part II. *Hospital Pharm*. 1994;29(12):1136-1137.
3. Skaer TL, Huckleberry YC. Basic Bibliography: Biotechnology Pharmacoeconomics. *Hospital Pharm*. 2001;36(2):229-230.

#### TEXTBOOK CHAPTERS (peer-reviewed)

1. Skaer TL, Chapter 19: Sleep Deprivation and Economic Burden. In *Sleep Deprivation and Disease: Effects on the Body, Brain and Behavior*. Bianchi MT (ed), Massachusetts General Hospital Division of Sleep Medicine, Springer. Available November, 2013 p. 269-279. [Cited 2 times]
2. Skaer TL. Chapter 6: Treatment of Insomnia with Comorbid Mental Illness. In: *Can't Sleep? Issues of Being an Insomniac* [ISBN 978-953-307-763-5], 2012 Online open access textbook, InTech. DOI: 10.5772/32324; 03/2012. [Cited 1 time; Downloaded 2,790 times]
3. Skaer TL, Odell, C. Chapter 34: Mental Health. In: *Women's Health Across the Lifespan: A Pharmacotherapeutic Approach*. Bethesda, Maryland USA, Borgelt CM, O'Connell, MB, Smith JA, Calis KA, Editors. American Society of Health Systems Pharmacists. 2010:533-544.
4. Campbell LK, Robison LM, Skaer TL, Sclar DA. Depression: Medication Interventions and Their Effectiveness. In: *Managing Depressive Disorders*. Palmer KJ, Editor. Auckland, New Zealand: Adis International, Ltd. 2000:1-15. [Cited 9 times]
5. Skaer TL, Sclar DA, Robison LM. Why Controversy Exists Over the Benefits of Newer Antidepressants. In: *Controversies in Depression Management*. Lewis LV, Editor. Auckland, New Zealand: Adis International, Ltd. 2000:81-91.
6. Sclar DA, Skaer TL, Chapter 9: Effect of medication utilization review on Medicaid Health Care Expenditures: A Case Study of Patients with noninsulin Dependent Diabetes Mellitus. In: *Studies in Pharmaceutical Economics*. Smith MC, Editor. London, England: Routledge (Haworth Press). 1996:129. [Cited 10 times]

#### SELECTED ABSTRACTS: 116 total [1990-present].

1. Orr MF, Smith CL, Skaer TL, Howell DN, Barbosa-Leiker C, Dyck D. Framework Analysis in Prevention: Developing communication between researchers and chronic pain. Society for Prevention Research Annual Meeting, San Francisco, California, June 2, 2016.
2. Skaer TL, Nwude A, Male Ervik AL. State of Washington Opioid Prescription Guidelines for the Management of Chronic Non-cancer Pain. 34th Annual Scientific Meeting of the American Pain Society, Palm Springs, California, May 14, 2015. *J Pain* 2015;16(4):S86.
3. Skaer TL, Sclar DA, Robison LM. Trend in Anxiety Disorders in the United States 1990-2003. Washington State University 2009 Academic Showcase. Pullman, Washington, March 27, 2009.
4. Duvall CK, Neumiller JJ, Sclar DA, Robison LM, Setter SM, Skaer TL. Rate of Obesity in U.S. Ambulatory Patients with Diabetes Mellitus: A National Assessment of Office-Based Physician Visits. Proceedings of the

- 43rd Midyear Clinical Meeting of the American Society of Health-System Pharmacists. Orlando, Florida. December 9, 2008.
5. Wilson MN, Sclar DA, DuVall CK, Robison LM, Skaer TL, Undeberg MR. Ethnicity/Race, Use of Pharmacotherapy, and Scope of Physician Ordered Cholesterol Screening, and Provision of Diet/Nutrition or Exercise Counseling During U.S. Office-Based Visits by Patients with Hyperlipidemia. Proceedings of the 43rd Midyear Clinical Meeting of the American Society of Health-System Pharmacists. Orlando, Florida. December 9, 2008.
  6. Kelly BD, Sclar DA, Robison LM, Skaer TL. Rate of Use of Salmeterol, Fluticasone, and Formoterol Among U.S. Children and Adolescents Diagnosed with Asthma and Concordance with Treatment Guidelines. Proceedings of the 13th Annual Meeting of the Pediatric Pharmacy Advocacy Group. Baltimore, Maryland. October 3, 2008.
  7. Neumiller JJ, Sclar DA, Robison LM, Maldonado AL, Setter SM, Skaer TL. Ethnicity/Race and the Rate of Physician Ordered Hemoglobin A1c During U.S. Office-Based Visits by Patients with Diabetes Mellitus. Proceedings of the 68th Scientific Sessions of the American Diabetes Association. San Francisco, California. June 7, 2008.
  8. Sclar DA, Robison LM, Skaer TL. Encore Presentation: Prevalence of Co-administration of a Triptan and an Antidepressant in the United States: A Risk for Serotonin Syndrome. Proceedings of the 21st American College of Clinical Pharmacy 2008 Spring Practice and Research Forum Phoenix, AZ April 7, 2008.
  9. Sclar DA, Robison LM, Skaer TL. Is ADHD Increasing Among U.S. Adults: Trends in Diagnosis and Pharmacotherapy Treatment, 1995-2004. Proceedings of the American College of Clinical Pharmacy 2008 Spring Practice and Research Forum. Phoenix, AZ April 7, 2008.
  10. Robison LM, Sclar DA, Skaer TL. Trends in Diagnosis and Treatment of ADHD among United States Adults: 1995-2004. The 16th European Congress of Psychiatry (AEP 2008). Nice France April, 2008 *Eur Psychiatry*. 2008, 23 (Suppl 2): S392.
  11. Robison LM, Sclar DA, Skaer TL. ADHD and Stimulant Use Among Girls in the USA: A Trend analysis by Gender. The 16th European Congress of Psychiatry (AEP 2008). Nice France April, 2008. *European Psychiatry* 2008, (Suppl 2): S392.
  12. Sclar DA, Robison LM, Gavrun C, Skaer TL. Payers Influence on Length of Stay for Depression Among Children. 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Boston, MA October 26, 2007.
  13. Sclar DA, Robison LM, Skaer TL. Prevalence of A Diagnosis of Depression or Schizophrenia and Discharged Against Medical Advice: A National Assessment of U.S. Hospital Admissions. Proceedings of the 19<sup>th</sup> World Congress of the World Association for Social Psychiatry. Prague, Czech Republic. October 21, 2007.
  14. Sclar DA, Robison LM, Skaer TL. Prevalence of Co-administration of an Antidepressant and a Triptan in the United States: A Risk for Serotonin Syndrome. 20th Annual Meeting of the European College of Neuropsychopharmacology Congress. Vienna, Austria October 16, 2007. *Eur Neuropsychopharmacol*. 2007;17(Suppl 4):S348.
  15. Skaer TL, Sclar DA, Robison LM. Trend in Anxiety Disorders in the United States 1990-2003. 6th World Congress on Stress. Vienna, Austria October 12, 2007.
  16. Sclar DA, Skaer TL, Robison LM. Trend in Depression Treatment Modalities for U.S. Children and Adolescents. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. San Diego, CA October 25, 2006.
  17. Skaer TL, Robison LM, Sclar DA. Antidepressant Trends Among Children and Adolescents Diagnosed with Depression: 1990-2001. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry. San Diego, CA October 25, 2006
  18. Sclar DA, Skaer TL, Robison LM. Disparity in Rates of Depression and Antidepressant Use by Ethnicity / Race. 58th Institute on Psychiatric Services of the American Psychiatric Association, New York, NY, October 5, 2006.
  19. Sclar DA, Skaer TL, Robison LM. Sedative / Hypnotic Use and Trends Among United States Elderly. 19th European Congress of Neuropsychopharmacology. Paris, France, September 17, 2006. *Eur Neuropsychopharmacol*. 2006;16(Suppl 4):S554.
  20. Robison LM, Sclar DA, Skaer TL. Diagnosis and Treatment of ADHD in Adults: 2001-2004. 58th Institute on Psychiatric Services of the American Psychiatric Association, New York, NY, October 5, 2006.
  21. Sclar DA, Skaer TL, Robison LM. Disparity In The Rate Of Depression and Use of Antidepressants In The USA By Ethnicity / Race: 1992-2003. 19th European Congress of Neuropsychopharmacology. Paris, France, September 17, 2006. *Eur Neuropsychopharmacol*. 2006;16(Suppl 4):S360.

22. Sclar DA, Robison LM, Skaer TL. Does Payer Type Influence Treatment Modality Among Adults With Depression? 12th Academy Health Annual Research Meeting. Seattle, WA, June 27, 2006.
23. Sclar DA, Skaer TL, Robison LM. Disparity in the Rate of Diagnosis of Depression and Use of Antidepressant Pharmacotherapy By Ethnicity / Race: An Assessment of U.S. Office-Based Visits, 1992-2003. 12th Academy Health Annual Research Meeting. Seattle, WA, June 27, 2006.
24. Skaer TL, Robison LM, Sclar DA. ADHD and Stimulant Use in the U.S. by Gender: A 12-Year Perspective. World Psychiatric Association Juan José López Ibor Centennial Congress. Madrid, Spain, April 19, 2006. *Actas Españolas de Psiquiatría*. 2006;34(Suppl 1):91.
25. Robison LM, Sclar DA, Skaer TL. Trend in ADHD and Stimulant Use Among Adults in the USA. World Psychiatric Association Juan José López Ibor Centennial Congress. Madrid, Spain, April 19, 2006. *Actas Españolas de Psiquiatría*. 2006;34(Suppl 1):90.
26. Robison LM, Sclar DA, Skaer TL. Trends in ADHD and Stimulant Use Among U.S. Adults: 1995-2002. 18th Congress of the European College of Neuropsychopharmacology. Amsterdam, The Netherlands, October 24, 2005. *Eur Neuropsychopharmacol*. 2005;15(Suppl 3):S649.
27. Robison LM, Sclar DA, Skaer TL. Trends in ADHD and Stimulant Use Among US Adults: 1995-2002. 57th Institute on Psychiatric Services. San Diego, California. October 7, 2005.
28. Sclar DA, Skaer TL, Robison LM. Payer Type Influence Treatment Method in Adults with Depression? 57th Institute on Psychiatric Services. San Diego, California. October 5, 2005.
29. Sclar DA, Evans MA, White JR, Skaer TL. Economics of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Therapy for Type 2 Diabetes. European Association for the Study of Diabetes 41st Annual Meeting. Athens, Greece. September 13, 2005
30. Sclar DA, Evans MA, White JR, Skaer TL, Robison LM. Economics of Basal Insulin Added to Oral Agents Versus Twice-Daily Insulin as Initial Therapy for Type 2 Diabetes Mellitus. Proceedings of the 65th Scientific Sessions of the American Diabetes Association. San Diego, California. June 12, 2005. *Diabetes* 2005;54(Suppl 1):A607.
31. Robison LM, Sclar DA, Skaer TL. ADHD and Stimulant Use by Gender: A 12-Year Perspective in the U.S. Proceeding of the Society for Research in Child Development 2005 Biennial Meeting. Atlanta, Georgia. April 9, 2005.
32. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poullos NS. Epidemiologic Modeling of Direct Cost-Avoidance Associated with Use of Full-Length Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM) Under Theoretical Emergence of a Novel Blood [Plasma] Borne Virus Infecting Previously Treated Persons with Hemophilia A. Proceedings of the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Hamburg, Germany. October 25, 2004. *Value in Health*. 2004;7(6):732.
33. Sclar DA, Skaer TL, Robison LM. Antidepressant Prescribing Trends Among U.S. Children and Adolescents Diagnosed with Depression: 1990-2001. Proceedings of the 19th Biennial Meeting of the World Psychiatric Association. Florence, Italy. November 12, 2004.
34. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poullos NS. Anti-D Immunoglobulin in the Treatment of Immune Thrombocytopenic Purpura in Adults: An Evaluation of Clinical Outcomes and Resource Utilization in Spain. Proceedings of the 20th Congress of the Spanish Society for Thrombosis and Hemostasis. Valencia, Spain. October 21, 2004.
35. Sclar DA, Moore TR, Robison LM, Skaer TL. Anxiety Disorders in the United States 1990-2001; Trend in Compliant, Diagnosis, Use of Pharmacotherapy, and Diagnosis of Comorbid Depression. Proceedings of the 16th Annual Meeting of the American College of Clinical Pharmacy. Dallas, Texas October 25, 2004. *Pharmacotherapy*. 2004;10:1457. [Cited 1 time]
36. Sclar DA, Skaer TL, Robison LM. Treatment Modalities for Depression Among U.S. Children and Adolescents. Proceedings of the 16th Annual Meeting of the American College of Clinical Pharmacy. Dallas, Texas. October 24, 2004.
37. Sclar DA, Robison LR, Skaer TL. Treatment modalities for depression among U.S. children and adolescents. Proceedings of the 56th Institute on Psychiatric Services, Atlanta, Georgia, October 9, 2004.
38. Sclar DA, Moore TR, Skaer TL, Robison LR. Trends in the use of SSRI antidepressants for children and adolescents diagnosed with depression. Proceeding of the 56th Institute on Psychiatric Services, Atlanta, Georgia, October 7, 2004.
39. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poullos NS. Anti-D Immunoglobulin in the Treatment of Immune Thrombocytopenic Purpura in Adults: An Evaluation of Clinical Outcomes and

- Resource Utilization in Germany. Proceedings of the 24th Annual Meeting of the German, Austrian, and Swiss Societies for Oncology and Hematology. Innsbruck, Austria. October 3, 2004.
40. Skaer TL, Sclar DA, Robison LM. Antidepressant Trends Among Children and Adolescents Diagnosed with Depression: 1990-2001. Proceedings of the 44th Annual U.S. National Institute of Mental Health New Clinical Drug Evaluation Unit Meeting. Phoenix, Arizona. June 2, 2004.
  41. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poullos NS. Aralast [Alpha1 Proteinase Inhibitor (Human)] In The Treatment Of Hereditary Emphysema Secondary To Alpha1-Antitrypsin Deficiency: Effect On Life-Years Gained. Proceedings of the 100th International Conference of the American Thoracic Society. Orlando, Florida. May 21, 2004.
  42. Sclar DA, Moore TR, Skaer TL, Robison LM. Use of SSRI Antidepressants Among U.S. Children and Adolescents. Proceedings of the 157th Annual Meeting of the American Psychiatric Association. New York, New York. May 3, 2004.
  43. Sclar DA, Skaer TL, Robison LM. Treatment Modalities for Depression Among U.S. Children and Adolescents. Proceedings of the 157th Annual Meeting of the American Psychiatric Association. New York, New York. May 3, 2004.
  44. Skaer TL, Robison LM, Sclar DA. Antidepressant Prescribing Trends Among U.S. Children and Adolescents Diagnosed with Depression: 1990-2001. Proceedings of the 157th Annual Meeting of the American Psychiatric Association. New York, New York. May 3, 2004.
  45. McCord SK, Skaer TL, Croft VF. PubMed and Beyond: Information Resources for Patient Care and Research. Proceedings of the 13th Annual Western Migrant Stream Forum. Seattle, Washington. January 30, 2004.
  46. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poullos NS. Epidemiologic Modeling of Direct Cost-Avoidance Associated with Use of Full-Length Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM) Under Theoretical Emergence of a Novel Blood [Plasma] Borne Virus Infecting Previously Treated Persons with Hemophilia A. Proceedings of the 45th Annual Meeting of the American Society of Hematology. San Diego, California. December 7, 2003. *Blood*. 2003;102(11)(Part 2):506b.
  47. Robison LM, Skaer TL, Sclar DA. Attention-Deficit / Hyperactivity Disorder and Stimulant Use Among U.S. Girls: Trends Over the Past Decade. Proceedings of the 53rd Annual Meeting of the Canadian Psychiatric Association. Halifax, Nova Scotia, Canada. November 1, 2003.
  48. Skaer TL, Sclar DA, Robison LM. Antidepressant Treatment Patterns Among Children and Adolescents Diagnosed with Depression: An Assessment of U.S. Office-Based Physician-Patient Encounters 1990-2001. Proceedings of the 55th Institute on Psychiatric Services of the American Psychiatric Association. Boston, Massachusetts. October 30, 2003.
  49. Robison LM, Skaer TL, Sclar DA. Attention-Deficit / Hyperactivity Disorder and Stimulant Use Among U.S. Girls: Trends Over the Past Decade. Proceedings of the 12th International Congress of the European Society for Child and Adolescent Psychiatry. Paris, France. September 30, 2003. *Eur Child Adolesc Psychiatry*. 2003;12(Suppl 2):I/150.
  50. Sclar DA, Skaer TL, Robison LM, Markowitz JS, DeVane CL, Dickson WM. Use and Cost Patterns of Risperidone Versus Olanzapine for the Treatment of Schizophrenia Among U.S. Children and Adolescents 5-18 Years Old. Proceedings of the 12th International Congress of the European Society for Child and Adolescent Psychiatry. Paris, France. October 1, 2003. *Eur Child Adolesc Psychiatry*. 2003;12(Suppl 2):I/219.
  51. Sclar DA, Skaer TL, Robison LM, Markowitz JS, DeVane CL, Dickson WM. Cost of Use Patterns for Atypical Antipsychotics by Race. Proceedings of the 55th Institute on Psychiatric Services of the American Psychiatric Association. Boston, Massachusetts. October 30, 2003.
  52. Skaer TL, Sclar DA, Robison LM. Antidepressant Treatment Patterns Among Children and Adolescents Diagnosed with Depression: An Assessment of U.S. Office-Based Physician-Patient Encounters 1990-2001. Proceedings of the 12th International Congress of the European Society for Child and Adolescent Psychiatry. Paris, France. September 30, 2003. *Eur Child Adolesc Psychiatry*. 2003;12(Suppl 2):I/218.
  53. Sclar DA, Skaer TL, Robison LM, Markowitz JS, DeVane CL, Dickson WM. Use and Cost Patterns of Risperidone Versus Olanzapine for the Treatment of Schizophrenia Among U.S. Children and Adolescents 5-18 Years Old. Proceedings of the 16th European Congress on Neuropsychopharmacology. Prague, Czech Republic. September 21, 2003. *Eur Neuropsychopharmacol*. 2003;13(Suppl 4):S281. [Cited 3 times]
  54. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poullos NS. Anti-D Immunoglobulin in the Treatment of Immune Thrombocytopenic Purpura in Adults in the United Kingdom: An Evaluation of Clinical Outcomes and Resource Utilization. Proceedings of the 19th Congress of the International Society on Thrombosis and Haemostasis. Birmingham, England. July 17, 2003. *J Thrombosis Haemostasis* 2003;89(Suppl 1):1158.



55. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poulios NS. Economic Modeling of Full-length Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM), Versus B-Domain Deleted rFVIII (BDDrFVIII) in Previously Treated Persons with Hemophilia A. Proceedings of the 19th Congress of the International Society on Thrombosis and Haemostasis. Birmingham, England. July 17, 2003. *J Thrombosis Haemostasis*. 2003;89(Suppl 1):1140.
56. Sclar DA, Skaer TL, Robison LM, Markowitz JS, DeVane CL, Dickson WM. Cost of Use Patterns for Atypical Antipsychotics Among Medicaid Beneficiaries in the United States. Proceedings of the 263rd Annual Meeting of the British Royal College of Psychiatrists. Edinburgh, Scotland. July 1, 2003.
57. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poulios NS. Aralast [Alpha1 Proteinase Inhibitor (Human)] in the Treatment of Hereditary Emphysema Secondary to Alpha1-Antitrypsin Deficiency: Effect on Life-Years Gained. Proceedings of the 12th Alpha-1 Foundation Conference. Chicago, Illinois. June 1, 2003.
58. Sclar DA, Skaer TL, Robison LM, Markowitz JS, DeVane CL, Dickson WM. Cost of Use Patterns for Atypical Antipsychotics Among Medicaid Beneficiaries in South Carolina. Proceedings of the 156th Annual Meeting of the American Psychiatric Association. San Francisco, California. May, 19, 2003.
59. Sclar DA, Skaer TL, Robison LM, Markowitz JS, DeVane CL, Dickson WM. Use Patterns for Atypical Antipsychotics Among Medicaid Beneficiaries in South Carolina. Proceedings of the 156th Annual Meeting of the American Psychiatric Association. San Francisco, California. May, 19, 2003.
60. Robison LM, Skaer TL, Sclar DA. Diagnosis of Depression and Use of Antidepressant Pharmacotherapy Among Elderly Patients with Parkinson's Disease or Diabetes Mellitus. Proceedings of the 10th International Psychogeriatric Association European and Mediterranean Meeting. Rome, Italy. April 18, 2002.
61. Sclar DA, Skaer TL, Robison LM, Evans MA, Chung KC, Li-McLeod J, Poulios NS. Anti-D Immunoglobulin in the Treatment of Immune Thrombocytopenic Purpura in Adults in the United Kingdom: An Evaluation of Clinical Outcomes and Resource Utilization. Proceedings of the 43rd Annual Scientific Meeting of the British Society for Haematology. Glasgow, Scotland. April 9, 2003. *Br J Haematology* 2003;121(Suppl 1):94.
62. Sclar DA, Skaer TL, Robison LM, Dickson MW, DeVane CL, Markowitz JS. Factors Influencing the Prescribing of Atypical Antipsychotic Pharmacotherapy: Does Age Matter? Proceedings of the International Psychogeriatric Association European Regional Meeting. Geneva Switzerland. April 2, 2003.
63. Robison LM, Skaer TL, Sclar DA, Galin RS. Is the Prevalence of Attention-Deficit / Hyperactivity Disorder Increasing Among U.S. Girls? Trends in Diagnosis and the Prescribing of Stimulants. Proceedings of the 41st U.S. National Institute of Mental Health New Clinical Drug Evaluation Unit Meeting. Phoenix, Arizona. May 29, 2001.
64. Skaer TL, Sclar DA, Robison LM, Galin RS. Women and Anxiety: Prevalence, Pharmacotherapy, and Comorbidity. Proceedings of the 3rd Annual Yale University Conference on Women's Health and Fitness. New Haven, Connecticut. October 27, 2000.
65. Skaer TL, Sclar DA, Robison LM, Galin RS. Factors Influencing Women's Access to Newer Antidepressants. Proceedings of the 3rd Annual Yale University Conference on Women's Health and Fitness. New Haven, Connecticut. October 27, 2000.
66. Skaer TL, Sclar DA, Robison LM, Galin RS. National Trends in the Prevalence of Attention-Deficit / Hyperactivity Disorder and the Prescribing of Methylphenidate Among School-Age Children: 1990-1997. Proceedings of the 3rd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists. Washington, D.C. April 7, 2000.
67. Sclar DA, Skaer TL, Robison LM, Galin RS. Prescribing Patterns for Antidepressant Pharmacotherapy, Diagnosis of Depression, and Receipt of Psychotherapy Among Children and Adolescents: 1990-1995. Proceedings of the 39th U.S. National Institute of Mental Health New Clinical Drug Evaluation Unit Meeting. Boca Raton, Florida. June 3, 1999.
68. Skaer TL, Sclar DA, Robison LM, Harding GH. Cancer Screening Knowledge, Determinants, and Intervention Among Hispanic Women Utilizing Migrant Health Clinics in Eastern Washington State. Proceedings of the 1st Inland Northwest Cancer Conference. Spokane, Washington. November 5, 1999.
69. Robison LM, Sclar DA, Skaer TL. Managed Care and Antidepressant pharmacotherapy: Economic Considerations. *Eur Neuropsychopharmacol*. 1996:6.

## INVITED PRESENTATIONS

- |      |  |
|------|--|
| 2017 | Timber Products Manufacturers Monthly Meeting. Spokane, Washington [January 26 2017]   |
| 2016 | Washington State Pharmacy Association, Annual Meeting; <i>Mindfulness-Based Interventions to Reduce Polypharmacy in Mental Health and Chronic Pain</i> . Suquamish, Washington [October 7, 2016] |

2012	American Pharmaceutical Association, Annual Conference; <i>Gender Differences in Chronic Pain, Depression, and Anxiety</i> . New Orleans, Louisiana [March 11, 2012]
2012	Mukogawa Fort Wright Institute, <i>Complementary and Alternative Medicine in the US</i> , Spokane, WA
2012	Spokane Pharmacists Association, December Continuing Education Lecture, Spokane, WA
2002	American College of Clinical Pharmacy, Annual Conference; Albuquerque, New Mexico
2001	Harvard University School of Medicine / Massachusetts General Hospital, Department of Psychiatry; Boston, Massachusetts
2000	Academy of Managed Care Pharmacy, Annual Conference; San Diego, California
2000	American Society of Health-System Pharmacists, Midyear Clinical Meeting; Las Vegas, Nevada
2000	2nd Inland Northwest Cancer Conference; Spokane, Washington
1999	World Health Organization, Conference on Depression; London, England
1999	1st Inland Northwest Cancer Conference; Spokane, Washington
1996	Ministry of Health, New Zealand; Auckland, New Zealand

## STUDENT PRECEPTING AND MENTORING

### Pharmacotherapy Research Projects

2014-2015	Amanda C. Helmann, Pharm.D. Candidate 2016
2013-2015	Azuka Nwude, Pharm.D. Candidate 2015 (Supported by a student fellowship grant from the WSU Alcohol and Drug Abuse Research Program)
2013-2015	Anne Louise Male Ervik, Pharm.D. Candidate 2015 (Supported by a student fellowship grant from the WSU Alcohol and Drug Abuse Research Program)
2013-2014	James Leonard, Pharm.D. Candidate 2016
1998-1999	Hollie S. Leitzelar, Pharm.D.
1998-1999	Lloyd D. Stever, Pharm.D.
1995-1996	Dianne K. Ambrosewicz, B.Pharm.
1994-1995	Garrett A. Lau, B.Pharm.
1994-1995	Jason L. Iltz, B.Pharm., Pharm.D.

### Scholarship in Geriatric Pharmacology (Supported by a grant from Merck / American Federation for Aging Research)

2000-2001	Yvonne C. Huckleberry, B.S., Pharm.D.
-----------	---------------------------------------

### University Honors Program Thesis

2001-2003	Pamela A. Cain, B.S. Candidate (Supported by a grant from Washington State University Alcohol and Drug Abuse Program)
2001-2003	Amanda A. Powers, B.S. Candidate, (Supported by a grant from Washington State University Alcohol and Drug Abuse Program)
2001-2002	Maren J. Kampfer, B.S.
1994-1995	Cindy B. Wilson, B.Pharm., Pharm.D. (Supported by a grant from Boehringer Ingelheim)

### Pharmacotherapy Summer Research Program: Supported by a grant from Eli Lilly & Company

1994	Patrick J. O'Connor, B.Pharm.
1994	Lisa M. Williams, B.Pharm.

### Residency Program in Ambulatory Care: Supported by a grant from Boehringer Ingelheim

1992-1993	JoAnne K.H. Won, Pharm.D.
1992-1993	Daniel J. Markowski, Pharm.D.

### Fellowship Program in Pharmacoepidemiology: Supported by a grant from Eli Lilly and Company

1996-1998	Julie K. Stowers, Pharm.D., M.S.
-----------	----------------------------------

### Fellowship Program in Pharmacoeconomics: (Supported by a grant from Boehringer Ingelheim)

1993-1995	Bryan R. Key, B.Pharm., Ph.D.
-----------	-------------------------------

**THESIS COMMITTEE MEMBER**

2001-2002 Xiaohui Hou, B.S., MHPA (*Association of Faculty Women Research Award*) Thomas S. Foley  
Institute for Public Policy Graduate Fellowship)

February 14, 2018